Efficacy and Safety of Alogliptin Plus Metformin in Patients With Type 2 Diabetes

Overview[ - collapse ][ - ]

Purpose The purpose of this study is to evaluate the safety and effectiveness of alogliptin combined with metformin, once daily (QD) or twice daily (BID), in participants with Type 2 Diabetes.
ConditionDiabetes Mellitus, Type 2
InterventionDrug: Alogliptin
Drug: Metformin
Drug: Alogliptin Placebo
Drug: Metformin Placebo
PhasePhase 3
SponsorTakeda
Responsible PartyTakeda
ClinicalTrials.gov IdentifierNCT01023581
First ReceivedDecember 1, 2009
Last UpdatedFebruary 17, 2013
Last verifiedFebruary 2013

Tracking Information[ + expand ][ + ]

First Received DateDecember 1, 2009
Last Updated DateFebruary 17, 2013
Start DateNovember 2009
Estimated Primary Completion DateJune 2011
Current Primary Outcome MeasuresChange From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 26 [Time Frame: Baseline and Week 26.] [Designated as safety issue: No]The change from Baseline to Week 26 in HbA1c (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound).
Current Secondary Outcome Measures
  • Change From Baseline in HbA1c Over Time [Time Frame: Baseline and Weeks 4, 8, 12, 16, and 20.] [Designated as safety issue: No]The change from Baseline in HbA1c (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) was assessed at Weeks 4, 8, 12, 16 and 20.
    Least squares means are from an analysis of covariance (ANCOVA) model with treatment and geographic region as fixed effects, and baseline HbA1c as a covariate.
  • Change From Baseline in Fasting Plasma Glucose Over Time [Time Frame: Baseline and Weeks 1, 2, 4, 8, 12, 16, 20 and 26.] [Designated as safety issue: No]The change from Baseline in fasting plasma glucose was assessed at Weeks 1, 2, 4, 8, 12, 16, 20 and 26. Least Squares Means were from an ANCOVA model with treatment and geographic region as fixed effects, and baseline fasting plasma glucose as a covariate.

Descriptive Information[ + expand ][ + ]

Brief TitleEfficacy and Safety of Alogliptin Plus Metformin in Patients With Type 2 Diabetes
Official TitleA Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficacy and Safety of Alogliptin Plus Metformin, Alogliptin Alone, or Metformin Alone in Subjects With Type 2 Diabetes
Brief Summary
The purpose of this study is to evaluate the safety and effectiveness of alogliptin combined
with metformin, once daily (QD) or twice daily (BID), in participants with Type 2 Diabetes.
Detailed Description
There are approximately 19 million people in the United States who have been diagnosed with
diabetes mellitus, of which 90% to 95% are type 2. The prevalence of type 2 diabetes varies
among racial and ethnic populations and has been shown to correlate with age, obesity,
family history, history of gestational diabetes and physical inactivity. Over the next
decade, a marked increase in the number of adults with diabetes mellitus is expected.

Metformin is the usual choice of first-line therapy for type 2 diabetes. Metformin targets
insulin resistance in type 2 diabetes by inhibiting hepatic glucose production and
stimulating glucose uptake in skeletal muscle and adipose tissue, which results in a
long-term glucose-lowering effect.

Alogliptin is an inhibitor of the dipeptidyl peptidase IV enzyme. Dipeptidyl peptidase-4
enzyme is thought to be primarily responsible for the in vivo degradation of 2 peptide
hormones released in response to nutrient ingestion, namely glucagon-like peptide-1 and
glucose-dependent insulinotropic peptide. Both peptides exert important effects on islet
beta cells to stimulate glucose-dependent insulin secretion as well as regulating beta cell
proliferation and cytoprotection. Glucagon-like peptide-1, but not glucose-dependent
insulinotropic peptide, inhibits gastric emptying, glucagon secretion, and food intake.
Glucose-dependent insulinotropic peptide has been shown to enhance insulin secretion by
direct interaction with a glucose-dependent insulinotropic peptide -specific receptor on
islet beta cells. The glucose-lowering actions of glucagon-like peptide-1, but not
glucose-dependent insulinotropic peptide, are preserved in patients with type 2 diabetes
mellitus. It is expected that inhibition of dipeptidyl peptidase IV will improve glycemic
(glucose) control in patients with type 2 diabetes.

Based on the potential, complimentary mechanisms of action of alogliptin and metformin, this
study will compare the safety and efficacy of alogliptin and metformin (SYR-322MET) on
improving glycemic control in patients with type 2 diabetes mellitus who are inadequately
controlled by diet adjustment and exercise alone.

Participants taking part in this study will receive dietary and exercise coaching, and will
monitor their own blood glucose concentrations with a home glucose monitor. Participants
will also be required to maintain a hypoglycemic diary throughout the course of the study.
Participation in this study is expected to last up to 34 weeks.
Study TypeInterventional
Study PhasePhase 3
Study DesignAllocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
ConditionDiabetes Mellitus, Type 2
InterventionDrug: Alogliptin
Alogliptin tablets.
Other Names:
SYR-322Drug: Metformin
Metformin capsules
Other Names:
  • Glucophage
  • Glucophage XR
  • Riomet
  • Fortamet
  • Glumetza
  • Obimet
  • Dianben
  • Diabex
  • Diaformin
Drug: Alogliptin Placebo
Alogliptin placebo-matching tablets.
Drug: Metformin Placebo
Metformin placebo-matching capsules.
Study Arm (s)
  • Placebo Comparator: Placebo
    Alogliptin placebo-matching tablets, orally, twice daily and Metformin placebo-matching capsules, orally, twice daily for up to 26 weeks.
  • Experimental: Alogliptin 25 QD
    Alogliptin 25 mg, tablets, orally, once daily (QD) and Metformin placebo-matching capsules, orally, twice daily for up to 26 weeks.
  • Experimental: Alogliptin 12.5 BID
    Alogliptin 12.5 mg, tablets, orally, twice daily (BID) and Metformin placebo-matching capsules, orally, twice daily for up to 26 weeks.
  • Active Comparator: Metformin 500 BID
    Alogliptin placebo-matching tablets, orally, twice daily and Metformin 500 mg capsules, orally, twice daily for up to 26 weeks.
  • Active Comparator: Metformin 1000 BID
    Alogliptin placebo-matching tablets, orally, twice daily and Metformin 1000 mg capsules, orally, twice daily for up to 26 weeks.
  • Experimental: Alogliptin 12.5 BID + Metformin 500 BID
    Alogliptin 12.5mg, tablets, orally, twice daily and Metformin 500 mg, capsules, orally, twice daily for up to 26 weeks.
  • Experimental: Alogliptin 12.5 BID + Metformin 1000 BID
    Alogliptin 12.5 mg, tablets, orally, twice daily and Metformin 1000 mg, capsules, orally, twice daily for up to 26 weeks.

Recruitment Information[ + expand ][ + ]

Recruitment StatusCompleted
Estimated Enrollment784
Estimated Completion DateJune 2011
Estimated Primary Completion DateJune 2011
Eligibility Criteria
Inclusion Criteria:

- Has historical diagnosis of Type 2 Diabetes Mellitus.

- Has been treated with diet and exercise for at least 2 months prior to Screening, and
has a Glycosylated Hemoglobin concentration between 7.5% and 10.0%, inclusive at
Screening.

- Has received less than 7 days of any antidiabetic medication within 2 months prior to
Screening.

- Body mass index greater than or equal to 23 kg/m^2 and less than or equal to 45
kg/m^2 (except for Asian or Asian-descendant subjects for whom the range is between
20 and 35 kg/ m^2, inclusive).

- Fasting C-peptide concentration greater than or equal to 0.8 ng/mL.

- Regularly using other, non-excluded, medications must be on a stable dose for at
least the 4 weeks prior to Screening.

- Females of childbearing potential and males who are sexually active agree to
routinely use adequate contraception from Screening throughout the duration of the
study.

- Able and willing to monitor their own blood glucose concentrations with a home
glucose monitor and complete patient diaries.

Exclusion Criteria:

- Hemoglobin less than 12 g/dL for males and less than 10 g/dL for females at Screening
Visit.

- Has a history of any hemoglobinopathy that may affect determination of Glycosylated
Hemoglobin.

- Has a history of laser treatment for proliferative diabetic retinopathy within the 6
months prior to Screening.

- Has a history of treatment for diabetic gastric paresis, gastric banding, or gastric
bypass surgery.

- Has a history of diabetic ketoacidosis or hyperosmolar non-ketotic coma.

- Has systolic blood pressure greater than or equal to 150 mmHg and /or diastolic
pressure greater than or equal to 90 mmHg at Screening visit.

- Has New York Heart Association Class III to IV heart failure.

- Has a history of coronary angioplasty, coronary stent placement, coronary bypass
surgery, or myocardial infarction within the 90 days prior to Screening.

- Has Alanine aminotransferase greater than 3 times the upper limit of normal at
Screening.

- Has a history of alcohol or substance abuse with the 2 years prior to Screening.

- Serum creatinine greater than or equal to 1.5 mg/dL for males and greater than or
equal to 1.4 mg/dL for females.

- Has history of cancer, other than squamous cell or basal cell carcinoma of the skin
that has not been in full remission for at least 5 years prior to Screening.

- Has a history of infection with human immunodeficiency virus, hepatitis B virus or
hepatitis C virus.

- Has any major illness or debility that in the investigator's opinion prohibits the
subject from completing the study.

- Has received any investigational drug within the 90 days prior to Screening.

- Has a history of hypersensitivity or allergy to alogliptin, other DPP-4 inhibitors,
metformin or related compounds.

- Has used oral or systematically injected glucocorticoids or weight loss drugs prior
to 2 months to screening.
GenderBoth
Ages18 Years
Accepts Healthy VolunteersNo
ContactsNot Provided
Location CountriesUnited States, Czech Republic, Hungary, Israel, Lithuania, Mexico, Poland, Puerto Rico, Romania, Russian Federation, Slovakia, South Africa, Ukraine

Administrative Information[ + expand ][ + ]

NCT Number NCT01023581
Other Study ID NumbersSYR-322MET_302
Has Data Monitoring CommitteeYes
Information Provided ByTakeda
Study SponsorTakeda
CollaboratorsNot Provided
Investigators Study Director: Vice President, Clinical Science Takeda
Verification DateFebruary 2013

Locations[ + expand ][ + ]

United States, Alabama
Dothan, Alabama, United States
United States, Alabama
Muscle Shoals, Alabama, United States
United States, Alabama
Pell City, Alabama, United States
United States, Arizona
Chandler, Arizona, United States
United States, Arizona
Mesa, Arizona, United States
United States, Arizona
Phoenix, Arizona, United States
United States, Arizona
Sierra Vista, Arizona, United States
United States, Arizona
Tempe, Arizona, United States
United States, Arkansas
Little Rock, Arkansas, United States
United States, Arkansas
Searcy, Arkansas, United States
United States, Arkansas
Tempe, Arkansas, United States
United States, California
Anaheim, California, United States
United States, California
Buena Park, California, United States
United States, California
Cathedral City, California, United States
United States, California
National City, California, United States
United States, California
Pismo Beach, California, United States
United States, California
Roseville, California, United States
United States, California
Santa Ana, California, United States
United States, Colorado
Colorado Springs, Colorado, United States
United States, Florida
Boca Raton, Florida, United States
United States, Florida
Bradenton, Florida, United States
United States, Florida
Cutler Bay, Florida, United States
United States, Florida
Hialeah, Florida, United States
United States, Florida
Lauderdale Lakes, Florida, United States
United States, Florida
Miami, Florida, United States
United States, Florida
Ocala, Florida, United States
United States, Florida
Opa Locka, Florida, United States
United States, Florida
Orlando, Florida, United States
United States, Florida
Panama City, Florida, United States
United States, Florida
Pembroke Pines, Florida, United States
United States, Georgia
Atlanta, Georgia, United States
United States, Georgia
Blue Ridge, Georgia, United States
United States, Georgia
Decatur, Georgia, United States
United States, Georgia
Lawrenceville, Georgia, United States
United States, Idaho
Hayden Lake, Idaho, United States
United States, Illinois
Chicago, Illinois, United States
United States, Illinois
Melrose Park, Illinois, United States
United States, Indiana
La Porte, Indiana, United States
United States, Indiana
Mishawaka, Indiana, United States
United States, Iowa
Council Bluffs, Iowa, United States
United States, Iowa
Dubuque, Iowa, United States
United States, Kansas
Topeka, Kansas, United States
United States, Kentucky
Lexington, Kentucky, United States
United States, Kentucky
Louisville, Kentucky, United States
United States, Louisiana
Marrero, Louisiana, United States
United States, Maryland
Oxon Hill, Maryland, United States
United States, Massachusetts
North Dartmouth, Massachusetts, United States
United States, Michigan
Dearborn, Michigan, United States
United States, Michigan
Flint, Michigan, United States
United States, Michigan
Kalamazoo, Michigan, United States
United States, Mississippi
Picayune, Mississippi, United States
United States, Missouri
St. Louis, Missouri, United States
United States, Nebraska
Omaha, Nebraska, United States
United States, Nevada
Henderson, Nevada, United States
United States, Nevada
Las Vegas, Nevada, United States
United States, New Jersey
Brick, New Jersey, United States
United States, New Jersey
Elizabeth, New Jersey, United States
United States, New York
North Massapequa, New York, United States
United States, North Carolina
Asheville, North Carolina, United States
United States, North Carolina
Charlotte, North Carolina, United States
United States, North Carolina
Greensboro, North Carolina, United States
United States, North Carolina
Mooresville, North Carolina, United States
United States, North Dakota
Fargo, North Dakota, United States
United States, Ohio
Cincinnati, Ohio, United States
United States, Ohio
Cleveland, Ohio, United States
United States, Ohio
Gallipolis, Ohio, United States
United States, Ohio
Mason, Ohio, United States
United States, Ohio
Maumee, Ohio, United States
United States, Oklahoma
Norman, Oklahoma, United States
United States, Oklahoma
Oklahoma City, Oklahoma, United States
United States, Oklahoma
Tulsa, Oklahoma, United States
United States, Pennsylvania
Altoona, Pennsylvania, United States
United States, Pennsylvania
Bensalem, Pennsylvania, United States
United States, Pennsylvania
Downingtown, Pennsylvania, United States
United States, Pennsylvania
Fleetwood, Pennsylvania, United States
United States, Pennsylvania
Perkasie, Pennsylvania, United States
United States, Pennsylvania
Shippensburg, Pennsylvania, United States
United States, Pennsylvania
Tipton, Pennsylvania, United States
United States, Pennsylvania
Uniontown, Pennsylvania, United States
United States, South Carolina
Columbia, South Carolina, United States
United States, South Carolina
Greenville, South Carolina, United States
United States, South Carolina
Murrells Inlet, South Carolina, United States
United States, South Carolina
North Myrtle Beach, South Carolina, United States
United States, South Carolina
Taylors, South Carolina, United States
United States, Tennessee
Brentwood, Tennessee, United States
United States, Tennessee
Bristol, Tennessee, United States
United States, Tennessee
Crossville, Tennessee, United States
United States, Tennessee
Johnson City, Tennessee, United States
United States, Tennessee
McKenzie, Tennessee, United States
United States, Tennessee
Spring Hill, Tennessee, United States
United States, Texas
Carrollton, Texas, United States
United States, Texas
Dallas, Texas, United States
United States, Texas
Deer Park, Texas, United States
United States, Texas
El Paso, Texas, United States
United States, Texas
Houston, Texas, United States
United States, Texas
Hurst, Texas, United States
United States, Texas
Katy, Texas, United States
United States, Texas
Odessa, Texas, United States
United States, Texas
San Antonio, Texas, United States
United States, Texas
Schertz, Texas, United States
United States, Texas
Spring, Texas, United States
United States, Texas
Sugarland, Texas, United States
United States, Texas
Temple, Texas, United States
United States, Utah
Bountiful, Utah, United States
United States, Utah
Ogden, Utah, United States
United States, Utah
Salt Lake City, Utah, United States
United States, Vermont
South Burlington, Vermont, United States
United States, Virginia
Petersburg, Virginia, United States
United States, Wisconsin
Milwaukee, Wisconsin, United States
Czech Republic
Hradec Kralove, Czech Republic
Czech Republic
Olomouc, Czech Republic
Czech Republic
Ostrava, Czech Republic
Czech Republic
Praha 10, Czech Republic
Czech Republic
Zlin, Czech Republic
Czech Republic
Znojmo, Czech Republic
Hungary
Budaors, Hungary
Hungary
Debrecen, Hungary
Hungary
Gyongyos, Hungary
Hungary
Gyor, Hungary
Hungary
Gyula, Hungary
Hungary
Komarom, Hungary
Hungary
Szolnok, Hungary
Hungary
Zalaegerszeg, Hungary
Israel
Haifa, Israel
Israel
Holon, Israel
Israel
Kfar Saba, Israel
Israel
Nahariya, Israel
Israel
Safed, Israel
Lithuania
Kaunas, Lithuania
Lithuania
Kedainiai, Lithuania
Lithuania
Klaipeda, Lithuania
Lithuania
Vilnius, Lithuania
Mexico
Acapulco, Guerrero, Mexico
Mexico
Cuernavaca, Mexico
Mexico
Culiacan, Sinoloa, Mexico
Mexico
Distrito Federal, Mexico
Mexico
Durango, Mexico
Mexico
Durango, Durango, Mexico
Mexico
Guadalajara, Mexico
Mexico
Mexico City, Mexico
Mexico
Mexico City, Mexico, Mexico
Mexico
Mexico, DF, Mexico
Mexico
Monclova, Coahuila, Mexico
Mexico
Monterrey, Mexico
Mexico
Monterrey, NL, Mexico
Mexico
Pachuca, Mexico
Mexico
Pachuca, Hidalgo, Mexico
Mexico
Saltillo, Mexico
Mexico
Tijuana, Baja California, Mexico
Mexico
Zapopan, Jalisco, Mexico
Poland
Bialystok, Poland
Poland
Bytom, Poland
Poland
Gniewkowo, Poland
Poland
Grodzisk Mazowiecki, Poland
Poland
Kamieniec Zabkowicki, Poland
Poland
Leczyca, Poland
Poland
Warszawa, Poland
Poland
Wroclaw, Poland
Puerto Rico
Caguas, Puerto Rico
Puerto Rico
Cidra, Puerto Rico
Puerto Rico
Ponce, Puerto Rico
Puerto Rico
Salinas, Puerto Rico
Puerto Rico
San Juan, Puerto Rico
Puerto Rico
Santurce, Puerto Rico
Puerto Rico
Trujilo Alto, Puerto Rico
Romania
Bacau, Romania
Romania
Baia Mare, Romania
Romania
Bucharest, Romania
Romania
Constanta, Romania
Romania
Iasi, Romania
Romania
Ploiesti, Romania
Russian Federation
Arkhangelsk, Russian Federation
Russian Federation
Irkutsk, Russian Federation
Russian Federation
Kemerovo, Russian Federation
Russian Federation
Moscow, Russian Federation
Russian Federation
Perm, Russian Federation
Russian Federation
St. Petersburg, Russian Federation
Russian Federation
Ufa, Russian Federation
Slovakia
Banska Bystrica, Slovakia
Slovakia
Kosice, Slovakia
Slovakia
Lucenec, Slovakia
Slovakia
Nitra, Slovakia
Slovakia
Presov, Slovakia
Slovakia
Prievidza, Slovakia
Slovakia
Sahy, Slovakia
Slovakia
Zilina, Slovakia
South Africa, Gauteng
Centurion, Gauteng, South Africa
South Africa, Gauteng
Johannesburg, Gauteng, South Africa
South Africa, Gauteng
Pretoria, Gauteng, South Africa
South Africa, Kwazulu-Natal
Durban, Kwazulu-Natal, South Africa
South Africa, Western Cape
Cape Town, Western Cape, South Africa
South Africa
Pretoria, South Africa
Ukraine
Dnipropetrovsk, Ukraine
Ukraine
Donetsk, Ukraine
Ukraine
Ivano-Frankivsk, Ukraine
Ukraine
Kharkiv, Ukraine
Ukraine
Kyiv, Ukraine
Ukraine
Lviv, Ukraine
Ukraine
Odesa, Ukraine
Ukraine
Vinnytsya, Ukraine
Ukraine
Zaporizhzhya, Ukraine